{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:29:30Z","timestamp":1785238170989,"version":"3.55.0"},"reference-count":8,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["155694"],"award-info":[{"award-number":["155694"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["openresearch.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["NIHR Open Res"],"abstract":"<ns3:p>Liver disease is a major, and increasing, cause of death in the UK. The UK Chronic Liver Failure network (UK-CLIF) was developed as a multi-stakeholder network with the aim to advance cirrhosis research, with emphasis on geographical areas of high disease prevalence or limited research activity. The process involved network development through dissemination and snowball sampling techniques, with monitoring of network development and connections between participants, developed over two online meetings. Network membership included representatives from patients, carers, clinicians, researchers, R&amp;D professionals, industry representatives, and the third sector. Subsequently, two facilitated in-person workshops were conducted with network participants. World Caf\u00e9 methodology and participant dot voting was used to develop areas of priority and consensus in: (i) research infrastructure for cirrhosis clinical trials, (ii) clinical factors affecting research delivery, and (iii) research priorities for future trials. Thematic analysis demonstrated that the need for patient-centric trial materials, a lack of resource for clinicians to participate in research, and variability in the standard of inpatient care for cirrhosis, were barriers for cirrhosis clinical trials. Future activities for UK-CLIF include participation in a process of quality standard setting for inpatient care for cirrhosis, and coordination of a James Lind Alliance Priority Setting Partnership to develop research questions for liver cirrhosis.<\/ns3:p>","DOI":"10.3310\/nihropenres.13669.1","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:30:07Z","timestamp":1730892607000},"page":"69","update-policy":"https:\/\/doi.org\/10.3310\/nihropenres.crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Decompensated Liver Cirrhosis Research Network (UK-CLIF): Building consensus for hepatology trials in the UK"],"prefix":"10.3310","volume":"4","author":[{"given":"Helen","family":"Crisp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Tavabie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvanne","family":"Enever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-8249","authenticated-orcid":false,"given":"Richard","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwar","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-8185","authenticated-orcid":false,"given":"Richard","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Jalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-359X","authenticated-orcid":false,"given":"Gautam","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref-1","article-title":"Liver disease profile, April 2024 update.","year":"2024"},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1334-45","DOI":"10.1111\/apt.15232","article-title":"Early and late mortality following unscheduled admissions for severe liver disease across England and Wales.","volume":"49","author":"S Roberts","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"ref-3","article-title":"NHS patients losing access to innovative treatments as UK industry clinical trials face collapse.","year":"2022"},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"264-66","DOI":"10.1136\/ejhpharm-2014-000520","article-title":"The European Statements of Hospital Pharmacy: achieving consensus using Delphi and World Caf\u00e9 methodologies.","volume":"21","author":"N Maskrey","year":"2014","journal-title":"Eur J Hosp Pharm."},{"key":"ref-6","article-title":"The 2nd atlas of variation in risk factors and healthcare for liver disease in England.","year":"2017"},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"151-9","DOI":"10.1016\/j.amjcard.2014.04.018","article-title":"Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.","volume":"114","author":"K Ferdinand","year":"2014","journal-title":"Am J Cardiol."},{"key":"ref-8","article-title":"Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review - final report.","year":"2023"},{"key":"ref-9","article-title":"Full government response to the Lord O'Shaughnessy review into commercial clinical trials.","year":"2023"}],"container-title":["NIHR Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T09:15:07Z","timestamp":1734081307000},"score":1,"resource":{"primary":{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":8,"URL":"https:\/\/doi.org\/10.3310\/nihropenres.13669.1","relation":{"has-review":[{"id-type":"doi","id":"10.3310\/nihropenres.14841.r33828","asserted-by":"subject"},{"id-type":"doi","id":"10.3310\/nihropenres.14841.r33693","asserted-by":"subject"},{"id-type":"doi","id":"10.3310\/nihropenres.14841.r33821","asserted-by":"object"},{"id-type":"doi","id":"10.3310\/nihropenres.14841.r33693","asserted-by":"object"},{"id-type":"doi","id":"10.3310\/nihropenres.14841.r33828","asserted-by":"object"}]},"ISSN":["2633-4402"],"issn-type":[{"value":"2633-4402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"Indexed","URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.3310\/nihropenres.14841.r33693, Cynthia L Hsu, University of California San Diego, San Diego, California, 05 Dec 2024, version 1, indexed","URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1#referee-response-33693","order":0,"name":"referee-response-33693","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.3310\/nihropenres.14841.r33828, Norberto Ch\u00e1vez-Tapia, Valeria M Fernandez-Garibay, Medica Sur Clinic, Mexico, 13 Dec 2024, version 1, indexed","URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-69\/v1#referee-response-33828","order":1,"name":"referee-response-33828","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This project is funded by the National Institute for Health and Care Research (NIHR) under its Health Technology Assessment (HTA) programme (Grant Reference Number 155694).  The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.\u202f. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This open access work is licensed under the Open Government Licence v3.0.","order":0,"name":"copyright-info","label":"Copyright"}]}}